<!DOCTYPE html>
<!-- Generated by pkgdown: do not edit by hand --><html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Safety Diagnostics for Dose Escalation • precautionary</title>
<!-- favicons --><link rel="icon" type="image/png" sizes="16x16" href="favicon-16x16.png">
<link rel="icon" type="image/png" sizes="32x32" href="favicon-32x32.png">
<link rel="apple-touch-icon" type="image/png" sizes="180x180" href="apple-touch-icon.png">
<link rel="apple-touch-icon" type="image/png" sizes="120x120" href="apple-touch-icon-120x120.png">
<link rel="apple-touch-icon" type="image/png" sizes="76x76" href="apple-touch-icon-76x76.png">
<link rel="apple-touch-icon" type="image/png" sizes="60x60" href="apple-touch-icon-60x60.png">
<!-- jquery --><script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js" integrity="sha256-CSXorXvZcTkaix6Yvo6HppcZGetbYMGWSFlBw8HfCJo=" crossorigin="anonymous"></script><!-- Bootstrap --><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.4.1/css/bootstrap.min.css" integrity="sha256-bZLfwXAP04zRMK2BjiO8iu9pf4FbLqX6zitd+tIvLhE=" crossorigin="anonymous">
<script src="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.4.1/js/bootstrap.min.js" integrity="sha256-nuL8/2cJ5NDSSwnKD8VqreErSWHtnEP9E7AySL+1ev4=" crossorigin="anonymous"></script><!-- bootstrap-toc --><link rel="stylesheet" href="bootstrap-toc.css">
<script src="bootstrap-toc.js"></script><!-- Font Awesome icons --><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/all.min.css" integrity="sha256-mmgLkCYLUQbXn0B1SRqzHar6dCnv9oZFPEC1g1cwlkk=" crossorigin="anonymous">
<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/v4-shims.min.css" integrity="sha256-wZjR52fzng1pJHwx4aV2AO3yyTOXrcDW7jBpJtTwVxw=" crossorigin="anonymous">
<!-- clipboard.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.6/clipboard.min.js" integrity="sha256-inc5kl9MA1hkeYUt+EC3BhlIgyp/2jDIyBLS6k3UxPI=" crossorigin="anonymous"></script><!-- headroom.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/headroom.min.js" integrity="sha256-AsUX4SJE1+yuDu5+mAVzJbuYNPHj/WroHuZ8Ir/CkE0=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/jQuery.headroom.min.js" integrity="sha256-ZX/yNShbjqsohH1k95liqY9Gd8uOiE1S4vZc+9KQ1K4=" crossorigin="anonymous"></script><!-- pkgdown --><link href="pkgdown.css" rel="stylesheet">
<script src="pkgdown.js"></script><meta property="og:title" content="Safety Diagnostics for Dose Escalation">
<meta property="og:description" content="Patient-centered safety diagnostics for oncology dose-escalation trials, accounting for inter-individual variation in PKPD.
">
<meta property="og:image" content="https://github.com/dcnorris/precautionary/raw/main/docs/card.png">
<meta property="og:image:alt" content="Logo for precautionary package">
<meta name="twitter:card" content="summary">
<meta name="twitter:creator" content="@davidcnorrismd">
<meta name="twitter:site" content="@davidcnorrismd">
<!-- mathjax --><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js" integrity="sha256-nvJJv9wWKEm88qvoQl9ekL2J+k/RWIsaSScxxlsrv8k=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/config/TeX-AMS-MML_HTMLorMML.js" integrity="sha256-84DKXVJXs0/F8OTMzX4UR909+jtl4G7SPypPavF+GfA=" crossorigin="anonymous"></script><!--[if lt IE 9]>
<script src="https://oss.maxcdn.com/html5shiv/3.7.3/html5shiv.min.js"></script>
<script src="https://oss.maxcdn.com/respond/1.4.2/respond.min.js"></script>
<![endif]-->
</head>
<body data-spy="scroll" data-target="#toc">
    <div class="container template-home">
      <header><div class="navbar navbar-default navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#navbar" aria-expanded="false">
        <span class="sr-only">Toggle navigation</span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <span class="navbar-brand">
        <a class="navbar-link" href="index.html">precautionary</a>
        <span class="version label label-danger" data-toggle="tooltip" data-placement="bottom" title="Unreleased version">0.2.5</span>
      </span>
    </div>

    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
<li>
  <a href="index.html">
    <span class="fas fa-home fa-lg"></span>
     
  </a>
</li>
<li>
  <a href="reference/index.html">Reference</a>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-expanded="false">
    Articles
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
<li>
      <a href="articles/DTP-vs-Korn94.html">DTP-vs-Korn94</a>
    </li>
    <li>
      <a href="articles/FDA-proactive.html">How FDA can vet dose-escalation trials for safety</a>
    </li>
    <li>
      <a href="articles/Intro.html">Introduction to package 'precautionary'</a>
    </li>
    <li>
      <a href="articles/MCSE-Free.html">MCSE-Free CRM Performance and Safety Assessment</a>
    </li>
    <li>
      <a href="articles/Safety-Schematic-via-CPE.html">Generalized dose-escalation safety schematics via Complete Path Enumeration (CPE)</a>
    </li>
  </ul>
</li>
<li>
  <a href="news/index.html">Changelog</a>
</li>
      </ul>
<ul class="nav navbar-nav navbar-right">
<li>
  <a href="https://github.com/dcnorris/precautionary/">
    <span class="fab fa-github fa-lg"></span>
     
  </a>
</li>
      </ul>
</div>
<!--/.nav-collapse -->
  </div>
<!--/.container -->
</div>
<!--/.navbar -->

      

      </header><div class="row">
  <div class="contents col-md-9">
<div id="precautionary-" class="section level1">
<div class="page-header"><h1 class="hasAnchor">
<a href="#precautionary-" class="anchor"></a>precautionary <img src="reference/figures/logo.svg" align="right" alt="LOGO" width="120">
</h1></div>
<!-- badges: start -->

<p><code>precautionary</code> implements new layers of patient-centered safety analysis for phase 1 dose-escalation trials, adding diagnostics to examine the safety characteristics of these designs in light of expected inter-individual variation in pharmacokinetics and pharmacodynamics. See Norris (2020b), “Retrospective analysis of a fatal dose-finding trial” <a href="https://arxiv.org/abs/2004.12755">arXiv:2004.12755</a> and (2020c) “What Were They Thinking? Pharmacologic priors implicit in a choice of 3+3 dose-escalation design” <a href="https://arxiv.org/abs/2012.05301">arXiv:2012.05301</a>.</p>
<div id="installation" class="section level2">
<h2 class="hasAnchor">
<a href="#installation" class="anchor"></a>Installation</h2>
<p>Releases starting with 0.2.3 incorporate fast numerics implemented in <a href="https://www.rust-lang.org">Rust</a>, a modern programming language that emphasizes performance and reliability—attributes crucial to applications such as the analysis of clinical trials.</p>
<p>These innovations have delayed review and acceptance by CRAN, pending which the newest features of <code>precautionary</code> will be available only here on GitHub.</p>
<div class="sourceCode" id="cb1"><pre class="downlit sourceCode r">
<code class="sourceCode R"><span class="co"># Install release version from GitHub</span>
<span class="fu">remotes</span><span class="fu">::</span><span class="fu"><a href="https://remotes.r-lib.org/reference/install_github.html">install_github</a></span><span class="op">(</span><span class="st">"dcnorris/precautionary"</span><span class="op">)</span>

<span class="co"># Install obsolete version from CRAN (where review of new Rust library remains pending)</span>
<span class="fu">install.package</span><span class="op">(</span><span class="st">"precautionary"</span><span class="op">)</span></code></pre></div>
<p>To date, those features of <code>precautionary</code> which depend on the Prolog code in <code>exec/prolog/</code> have been pre-built into the package, for example as the arrays <code>T[,,,]</code> written into <code>R/sysdata.rda</code> by <code>exec/make_sysdata_TUb.R</code>. Methodologists who wish to examine, recompute and verify these arrays are advised to install <a href="https://github.com/mthom/scryer-prolog">Scryer Prolog</a>.</p>
<p>It is a near-term goal for <code>precautionary</code> to reveal more transparently Prolog’s special contributions to its analysis of dose-escalation designs.</p>
</div>
<div id="usage" class="section level2">
<h2 class="hasAnchor">
<a href="#usage" class="anchor"></a>Usage</h2>
<p>Please see the vignettes under the <a href="#">Articles</a> tab above.</p>
</div>
<div id="references" class="section level2">
<h2 class="hasAnchor">
<a href="#references" class="anchor"></a>References</h2>
<p>The <code>precautionary</code> package is the pointy end of the spear in a larger <a href="https://precisionmethods.guru">DTAT research programme</a>, of which the following are key outputs. Several of these citations have accompanying online resources such as web applications. For the key references, lay explanations are available.</p>
<ol>
<li>
Norris DC. Dose Titration Algorithm Tuning (DTAT) should supersede ‘the’ Maximum Tolerated Dose (MTD) in oncology dose-finding trials. <i>F1000Research.</i> 2017;6:112. doi:<a href="https://f1000research.com/articles/6-112/v3">10.12688/f1000research.10624.3</a>. [<a href="https://precisionmethods.guru/2019/04/16/a-new-concept-may-help-us-at-last-abandon-one-size-fits-all-dosing-of-cancer-treatment-drugs/">lay explanation</a>]
</li>
<li>
–––––. Dose Titration Algorithm Tuning (DTAT) should supplant ‘the’ MTD. May 2017. [podium presentation] Symposium on Dose Selection for Cancer Treatment Drugs, Stanford Center for Innovative Study Design (CISD) May 12, 2017. doi:<a href="https://f1000research.com/slides/6-854">10.7490/f1000research.1114209.1</a>.
</li>
<li>
–––––. Costing ‘the’ MTD. <i>bioRxiv.</i> August 2017:150821. doi:<a href="https://www.biorxiv.org/content/10.1101/150821v3">10.1101/150821</a>. [<a href="https://precisionmethods.guru/2019/04/16/one-size-fits-all-dosing-of-cancer-treatment-drugs-how-much-does-it-cost-society/">lay explanation</a>]
</li>
<li>
–––––. Costing ‘the’ MTD: What Is the Economic and Human Cost of 1-Size-Fits-All Dose Finding in Oncology? [poster] Presented at 8th American Conference on Pharmacometrics (ACoP8), October 16, 2017. doi:<a href="https://f1000research.com/posters/6-1861">10.7490/f1000research.1114988.1</a>.
</li>
<li>
–––––. One-size-fits-all dosing in oncology wastes money, innovation and lives. <i>Drug Discovery Today.</i> 2018;23(1):4-6. doi:<a href="https://precisionmethods.guru/DTAT/Norris%20(2018)%20One-size-fits-all%20dosing%20in%20oncology%20wastes%20money,%20innovation%20and%20lives.pdf">10.1016/j.drudis.2017.11.008</a>. [<a href="https://precision-methodologies.shinyapps.io/thecost/">Shiny app</a>]
</li>
<li>
–––––. Precautionary Coherence Unravels Dose Escalation Designs. <i>bioRxiv.</i> December 2017:240846. doi:<a href="https://www.biorxiv.org/content/10.1101/240846v1">10.1101/240846</a>. [<a href="https://precisionmethods.guru/2019/04/14/the-conduct-of-most-first-in-human-oncology-drug-trials-is-conceptually-incoherent-and-unethical/">lay explanation</a>] [<a href="http://precisionmethods.guru/3+3/PC/">D3 app</a>]
</li>
<li>
–––––. Costing ‘the’ MTD … in 2-D. <i>bioRxiv.</i> July 2018:370817. doi:<a href="https://www.biorxiv.org/content/10.1101/370817v1">10.1101/370817</a> [<a href="https://precisionmethods.guru/2019/04/16/clinicians-must-regain-control-over-phase-1-cancer-combination-therapy-trials/">lay explanation</a>]
</li>
<li>
–––––. Ethical Review and Methodologic Innovation in Phase 1 Cancer Trials. <i>JAMA Pediatrics.</i> April 2019. doi:<a href="https://dx.doi.org/10.1001/jamapediatrics.2019.0811">10.1001/jamapediatrics.2019.0811</a> [<a href="https://precisionmethods.guru/2019/04/25/precautionary-coherence-for-irbs/">2-minute video</a>]
</li>
<li>
–––––. Impeachment of One-Size-Fits-All Dosing for Obstruction of Synergism. [working paper] December 4, 2019. doi:<a href="https://osf.io/3hcdb/">10.17605/OSF.IO/S7XDU</a>. [<a href="https://precisionmethods.guru/2020/01/13/therapeutic-synergism-and-the-statistician/">2-minute video</a>]
</li>
<li>
–––––. Comment on Wages et al., Coherence principles in interval-based dose finding. Pharmaceutical Statistics 2019, DOI: 10.1002/pst.1974. <i>Pharmaceutical Statistics.</i> March 2020. doi:<a href="https://onlinelibrary.wiley.com/doi/full/10.1002/pst.2016">10.1002/pst.2016</a> [<a href="https://precisionmethods.guru/2019/12/02/comment-on-wages-et-al-coherence-principles-in-interval-based-dose-finding/">additional background</a>]
</li>
<li>
–––––. Retrospective analysis of a fatal dose-finding trial. <a href="https://arxiv.org/abs/2004.12755">arXiv:2004.12755 [stat, q-bio]</a>. April 2020. [<a href="https://threadreaderapp.com/thread/1255095770627428352.html">Tweetorial</a>]
</li>
<li>
Norris DC, Sen S, Groisberg R, Subbiah V. Patient-Centered, Physician-Investigator Friendly Pragmatic Phase I/II Trial Designs—The 4P Model. <i>Mayo Clinic Proceedings.</i> 2020;95(11):2566-2568. doi:<a href="https://www.mayoclinicproceedings.org/article/S0025-6196(20)31039-9/fulltext">10.1016/j.mayocp.2020.09.009</a>
</li>
<li>
Norris DC. What Were They Thinking? Pharmacologic priors implicit in a choice of 3+3 dose-escalation design. <a href="https://arxiv.org/abs/2012.05301">arXiv:2012.05301 [stat, q-bio]</a>. December 9, 2020. [<a href="https://threadreaderapp.com/thread/1339219770730799106.html">Tweetorial</a>]
</li>
</ol>
</div>
</div>
  </div>

  <div class="col-md-3 hidden-xs hidden-sm" id="pkgdown-sidebar">
    <div class="links">
<h2>Links</h2>
<ul class="list-unstyled">
<li>Download from CRAN at <br><a href="https://cloud.r-project.org/package=precautionary">https://​cloud.r-project.org/​package=precautionary</a>
</li>
<li>Browse source code at <br><a href="https://github.com/dcnorris/precautionary/">https://​github.com/​dcnorris/​precautionary/​</a>
</li>
<li>Report a bug at <br><a href="https://github.com/dcnorris/precautionary/issues">https://​github.com/​dcnorris/​precautionary/​issues</a>
</li>
</ul>
</div>
<div class="license">
<h2>License</h2>
<ul class="list-unstyled">
<li>
<a href="https://opensource.org/licenses/mit-license.php">MIT</a> + file <a href="LICENSE-text.html">LICENSE</a>
</li>
</ul>
</div>
<div class="developers">
<h2>Developers</h2>
<ul class="list-unstyled">
<li>David C. Norris <br><small class="roles"> Author, maintainer, copyright holder </small> <a href="https://orcid.org/0000-0001-9593-6343" target="orcid.widget" aria-label="ORCID"><span class="fab fa-orcid orcid" aria-hidden="true"></span></a> </li>
<li><a href="authors.html">All authors...</a></li>
</ul>
</div>

  <div class="dev-status">
<h2>Dev status</h2>
<ul class="list-unstyled">
<li><a href="https://lifecycle.r-lib.org/articles/stages.html"><img src="https://img.shields.io/badge/lifecycle-maturing-blue.svg" alt="Lifecycle: maturing"></a></li>
<li><a href="https://github.com/dcnorris/precautionary/actions"><img src="https://github.com/dcnorris/precautionary/workflows/R-CMD-check/badge.svg" alt="R-CMD-check"></a></li>
</ul>
</div>
</div>
</div>


      <footer><div class="copyright">
  <p>Developed by David C. Norris.</p>
</div>

<div class="pkgdown">
  <p>Site built with <a href="https://pkgdown.r-lib.org/">pkgdown</a> 1.6.1.</p>
</div>

      </footer>
</div>

  


  </body>
</html>
